Literature DB >> 14678046

Sirolimus-induced pneumonitis: three cases and a review of the literature.

Ali A Haydar1, Mark Denton, Alex West, John Rees, David J A Goldsmith.   

Abstract

Interstitial pneumonitis is a rare disease that is seen in the context of some infections (e.g. PCP and CMV pneumonia), as side-effects of drugs (e.g. beta-blockers, amiodarone) and rarely in the context of renal transplantation. It manifests itself usually as a pneumonic illness; with symptoms of dyspnea, cough, fatigue and sometimes fever. Characteristic radiological changes are bilateral lower zone haziness. Interstitial pneumonitis is now emerging in solid organ transplant patients secondary to sirolimus). We describe three cases of sirolimus-induced pneumonitis in two patients who started sirolimus to permit cyclosporin withdrawal and in one patient initially started on sirolimus. The presentations in these cases ranged from insidious to fulminant; there was a rapid response to sirolimus withdrawal. This is an important syndrome, with an unknown frequency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678046     DOI: 10.1046/j.1600-6135.2003.00292.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

Review 1.  Overview of immunosuppression in liver transplantation.

Authors:  Anjana A Pillai; Josh Levitsky
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

2.  Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Authors:  Terry A Day; Keisuke Shirai; Paul E O'Brien; Maria Gisele Matheus; Kristina Godwin; Amit J Sood; Anvesh Kompelli; Julie A Vick; Daniel Martin; Lynn Vitale-Cross; Juan Luis Callejas-Varela; Zhiyong Wang; Xingyu Wu; Olivier Harismendy; Alfredo A Molinolo; Scott M Lippman; Carter Van Waes; Eva Szabo; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

Review 3.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Authors:  Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2019-02-27       Impact factor: 12.531

Review 4.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  The use of everolimus in renal-transplant patients.

Authors:  Julio Pascual
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-06-02

6.  Pulmonary toxicity in a renal transplant recipient treated with amiodarone and everolimus: a case of hypothetical synergy and a proposal for a screening protocol.

Authors:  Alberto Mella; Maria Messina; Andrea Ranghino; Paolo Solidoro; Giuseppe Tabbia; Giuseppe Paolo Segoloni; Luigi Biancone
Journal:  Case Rep Nephrol Urol       Date:  2014-04-12

Review 7.  Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.

Authors:  Patricia Lopez; Sven Kohler; Seema Dimri
Journal:  J Transplant       Date:  2014-12-18

Review 8.  mTOR co-targeting strategies for head and neck cancer therapy.

Authors:  Zhiyong Wang; Juan Callejas Valera; Xuefeng Zhao; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

9.  Low dose rapamycin exacerbates autoimmune experimental uveitis.

Authors:  Zili Zhang; Xiumei Wu; Jie Duan; David Hinrichs; Keith Wegmann; Gary L Zhang; Mark Hall; James T Rosenbaum
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.